Chiang Wan-Ni, Huang Po-Yu, Kuo Ho-Chang, Huang Ying-Hsien, Chang Ling-Sai
Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Department of Traditional Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Front Cardiovasc Med. 2023 Jun 12;10:1164530. doi: 10.3389/fcvm.2023.1164530. eCollection 2023.
In 2016, Lin et al. developed a prediction score of non-responsiveness to intravenous immunoglobulin (IVIG) in patients with Kawasaki disease (KD) (Lin et al., 2016). Various studies have attempted to validate the Formosa score, but inconsistent results have given us new opportunities and challenges. The aim of this meta-analysis is to explore the role of the Formosa score as a risk score in detecting IVIG-resistant KD patients and then compare the pooled sensitivity and specificity of four Asian risk scores, Egami, Formosa, Kobayashi, and Sano risk scores.
A comprehensive search of Cochrane, Embase, and PubMed was conducted through 20 December 2021, using key terms relevant to the research question "What are the sensitivities and specificities of the four Asian predicting scores, Egami, Formosa, Kobayashi, and Sano, in Kawasaki disease patients with IVIG resistance?" The reference lists of the included studies were manually reviewed to identify pertinent references. A random-effects bivariate model was used to estimate the summary of sensitivity and specificity of the tools.
We found 41 relevant studies of the four Asian risk scores that were eligible to analyze for pooled accuracy. Eleven studies involving 5,169 KD patients reported the diagnostic performance of the Formosa score for the risk of IVIG resistance. The overall performance of the Formosa score was as follows: pooled sensitivity, 0.60 [95% confidence interval (CI), 0.48-0.70]; pooled specificity, 0.59 (95% CI, 0.50-0.68); and area under the hierarchical summary receiver operating characteristic curve, 0.62. The Formosa score exhibited the highest sensitivity 0.76 (95% CI, 0.70-0.82) for detecting IVIG-resistant KD patients among the 21,389 children included in the 41 studies. In terms of specificity estimates, Formosa had the lowest specificity of 0.46 (95% CI, 0.41-0.51).
Patients at high risk for IVIG resistance may receive adjunctive treatment to reduce coronary lesions and thus also cardiovascular morbidity. Among all of the included studies, we found Formosa score to have the best sensitivity (0.76) but unsatisfactory specificity (0.46) for predicting IVIG resistance in Kawasaki disease. In the future, network meta-analysis should also incorporate the accuracy of the new scores after they have undergone a certain degree of validation around the world.
https://www.crd.york.ac.uk/PROSPERO/, PROSPERO CRD42022341410.
2016年,林等人开发了一种川崎病(KD)患者对静脉注射免疫球蛋白(IVIG)无反应的预测评分(林等人,2016年)。各种研究试图验证福尔摩沙评分,但结果不一致给我们带来了新的机遇和挑战。本荟萃分析的目的是探讨福尔摩沙评分作为风险评分在检测IVIG抵抗性KD患者中的作用,然后比较四个亚洲风险评分(江头、福尔摩沙、小林和佐野风险评分)的合并敏感性和特异性。
通过2021年12月20日对Cochrane、Embase和PubMed进行全面检索,使用与研究问题“四个亚洲预测评分(江头、福尔摩沙、小林和佐野)在IVIG抵抗性川崎病患者中的敏感性和特异性是多少?”相关的关键词。对纳入研究的参考文献列表进行人工审查,以识别相关参考文献。使用随机效应双变量模型来估计工具敏感性和特异性的汇总。
我们发现41项关于四个亚洲风险评分的相关研究符合纳入合并准确性分析的条件。11项涉及5169例KD患者的研究报告了福尔摩沙评分对IVIG抵抗风险的诊断性能。福尔摩沙评分的总体表现如下:合并敏感性为0.60[95%置信区间(CI),0.48 - 0.70];合并特异性为0.59(95%CI,0.50 - 0.68);分层汇总接受者操作特征曲线下面积为0.62。在41项研究纳入的21389名儿童中,福尔摩沙评分在检测IVIG抵抗性KD患者方面表现出最高敏感性0.76(95%CI,0.70 - 0.82)。就特异性估计而言,福尔摩沙评分的特异性最低,为0.46(95%CI,0.41 - 0.51)。
IVIG抵抗高危患者可能接受辅助治疗以减少冠状动脉病变,从而也降低心血管发病率。在所有纳入研究中,我们发现福尔摩沙评分在预测川崎病IVIG抵抗方面具有最佳敏感性(0.76)但特异性(0.46)不令人满意。未来,网络荟萃分析还应纳入新评分在全球范围内经过一定程度验证后的准确性。
https://www.crd.york.ac.uk/PROSPERO/,PROSPERO CRD42022341410。